FOXP3 gene polymorphism may contribute to the onset and progress of children immune thrombocytopenia

doi:10.3969/j.issn.1006-7795.2014.05.003

Abstract

Abstract:

Objective To investigate the association between FOXP3 gene polymorphism and the onset and progress of children immune thrombocytopenia (ITP), to explore the pathogenesis of childhood ITP. Methods A total of 328 patients of initial onset of ITP and 219 healthy individuals were enrolled into study group and controls group, respectively. FOXP3 polymorphisms: rs3761547, rs3761548 and rs2232365 were genotyped by the Sequenom SNP genotyping method. Patients were divided into two groups according to diagnosis and results of follow-up: "disease course exceeding 12 months"and "disease course within 12 months".Results The genotype rs2232365 AG was significantly higher in age-and sex-matched study group comparing to control group (P=0.013). Patients with rs2232365 G allele, rs3761547 GG genotype or G allele showed significantly higher in disease course exceeding 12 months sub-group than in disease course within 12 months sub-group (P=0.008, 0.001, 0.033 respectively).Conclusion The genotype rs2232365 polymorphism was associated with the pathogenesis of ITP; rs3761547 GG genotype and G alleles/ rs2232365 G allele may tend to have longer course and worse progress in children ITP. rs2232365 polymorphism was associated with progress of children ITP, which may play an important role in children ITP.

Key words: children, immune thrombocytopenia, FOXP3, single nucleotide polymorphism

CLC Number:

R725.5

Liu Fuhong, Chen Zhenping, Ma Jingyao, Wei Yunyun, Wu Runhui. FOXP3 gene polymorphism may contribute to the onset and progress of children immune thrombocytopenia[J]. Journal of Capital Medical University, 2014, 35(5): 539-544.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.05.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I5/539

References

[1] Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11): 2386-2393.
[2] Yeh H, Moore D J, Markmann J F, et al. Mechanisms of regulatory T cell counter-regulation by innate immunity[J]. Transplant Rev (Orlando), 2013, 27(2): 61-64.
[3] Janson P C, Winerdal M E, Marits P, et al. FOXP3 promoter demethylation reveals the committed Treg population in humans[J]. PLoS One, 2008, 3(2): e1612.
[4] Lee S M, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1[J]. Blood, 2008, 111(7): 3599-3606.
[5] Wang J D, Chang T K, Lin H K, et al. Reduced expression of transforming growth factor-β₁ and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP)[J]. Pediatr Blood Cancer,2011,57(4): 636-640.
[6] Aboul-Fotoh Lel-M, Abdel Raheem M M, El-Deen M A, et al. Role of CD4⁺ CD25⁺ T cells in children with idiopathic thrombocytopenic purpura[J]. Pediatr Hematol Oncol, 2011, 33(2): 81-85.
[7] Zahran A M, Elsayh K I. CD4⁺ CD25⁺ High Foxp3⁺regulatory T Cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut children Hospital[J]. Clin Appl Thromb Hemost,2014,20(1):61-67.
[8] Stelmaszczyk-Emmel A, Jackowska T, Rutkowska-Sak L, et al. Identification, frequency, activation and function of CD4⁺ CD25(high)FoxP3⁺⁺ regulatory T cells in chidhood with juvenile idiopathic arthritis[J]. Rheumatol Int, 2012, 32(5): 1147-1154.
[9] Atfy M, Amr G E, Elnaggar A M, et al. Impact of CD4⁺⁺CD25high regulatory T-cells and FoxP3 expression in the peripheral blood of patients with systemic lupus erythematosus[J]. Egypt J Immunol, 2009, 16(1): 117-126.
[10] Morgan M E,Van Bilsen J H,Bakker A M, et al. Expression of FOXP3 mRNA is not confined to CD4⁺^CD25⁺ T regulatory cells in humans [J]. Hum I mmunol, 2005, 66 (1): 13-20.
[11] 张春梅.免疫性血小板减少症患者淋巴细胞亚群表达及其与血小板抗体、临床特征的相关性研究[J]. 中国煤炭工业医学杂志,2012,15(10):1524-1526.
[12] 贲莹,张凤华,张冬.免疫细胞及相关细胞因子在格林-巴利综合征和实验性自身免疫性神经炎中的作用研究进展[J]. 解放军医药杂志,2013,25(2):14-16.
[13] Harbuz R, Lespinasse J, Boulet S, et al. Identification of new FOXP3 mutations and prenatal diagnosis of IPEX syndrome[J]. Prenat Diagn, 2010, 30(11): 1072-1078.
[14] Ban Y, Tozaki T, Tobe T, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts[J]. J Autoimmun, 2007, 28(4): 201-207.
[15] Chen Y, Zhang H, Liao W, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China[J]. J Exp Clin Cancer Res, 2013, 32: 39.
[16] Lan Y, Tang X S, Qin J, et al. Association of transcription factor FOXP3 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2010, 27(4): 433-436.
[17] Zhang J, Chen Y, Jia G, et al. FOXP3-3279 and IVS9+459 polymorphisms are associated with genetic susceptibility to myasthenia gravis[J]. Neurosci Lett, 2013, 534: 274-278.
[18] Song P, Wang X W, Li H X, et al. Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population[J]. Br J Dermatol, 2013,169(3):571-578.
[19] 张媛,王成硕,张罗.FOXP3基因多态性与变应性鼻炎的相关性研究[J]. 中华耳鼻喉头颈外科学杂志,2010, 45(5): 397-400.
[20] 娄玮,王成硕,张罗.调节性T细胞在过敏性鼻炎及抗原特异性免疫治疗中的作用[J]. 首都医科大学学报,2012,33(6):729-734.
[21] Qiu X Y, Jiao Z, Zhang M, et al. Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients[J]. Nephrology (Carlton), 2012, 17(4): 423-430.
[22] Wu Z G, You Z S, Zhang C, et al. Study on association of functional polymorphisms in Foxp3 gene with the susceptibility to unexplained recurrent spontaneous abortion [J]. Zhonghua Fu Chan Ke Za Zhi, 2011, 46(10): 763-768.
[23] Fodor E, Garaczi E, Polyanka H, et al. The rs3761548 polymorphism of FOXP3 is a protective genetic factor against allergic rhinitis in the Hungarian female population[J]. Hum Immunol, 2011, 72(10): 926-929.
[24] Gao L, Li K, Li F, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients[J]. J Dermatol Sci, 2010, 57(1): 51-56.
[25] Jahan P, Cheruvu R, Tippisetty S, et al. Association of FOXP3 (rs3761548) promoter polymorphism with nondermatomal vitiligo: A study from India[J]. J Am Acad Dermatol, 2013, 69(2): 262-266.
[26] Lin Y C, Lee J H, Wu A S, et al. Association of single-nucleotide polymorphisms in FOXP3 gene with systemic lupus erythematosus susceptibility: a case-control study[J]. Lupus, 2011, 20(2): 137-143.
[27] Andre G M, Barbosa C P, Teles J S, et al. Analysis of FOXP3 polymorphisms in infertile women with and without endometriosis[J]. Fertil Steril, 2011, 95(7): 2223-2227.
[28] D'Amico F, Skarmoutsou E, Marchini M, et al. Genetic polymorphisms of FOXP3 in Italian patients with systemic sclerosis[J]. Immunol Lett, 2013, 152(2): 109-113.
[29] Metz T D, Nelson L M, Stoddard G J, et al. FOXP3 gene polymorphisms in preeclampsia[J]. Am J Obstet Gynecol, 2012, 206(2): 165.e1-6.
[30] Xia G, Shah M, Luo X. Prevention of allograft rejection by amplification of Foxp3⁺CD4⁺CD25⁺ regulatory T cells[J]. Transl Res, 2009, 153(2): 60-70.
[31] Tang Q, Bluestone J A, Kang S M. CD4⁺Foxp3⁺ regulatory T cell therapy in transplantation[J]. J Mol Cell Biol, 2012, 4(1): 11-21.